1Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and 21 mutations treated with gefitinib or erlotinib[J].Clin Cancer Res, 2006,12 : 839- 845.
2Okabe T, Okamoto I, Tsukioka S, et al.Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinih resistance in non-small cell lung cancer cell lines with MET amplification[J].Clin Cancer Res,2009,15 : 907-913.
3Ercan D, Zejnullahu K, Yonesaka K, et al. Amplification of EGFR T790M causes resistance to an erreversihle EGFR inhibitor[J].Oneogene, 2010,29 : 2346-2351.
7Felip E,Cedres S, Peralta S, et al. Adjuvant chemotherapy in non- small cell lung cancer (NSCLC) [J]. Ann Oncol, 2007,18 :ix 143-153.
8Hu Y, Shen X, Lu H, et al.Tenacigenin B derivatives reverse P-glycoprotein-mediated multidrug resistance in HepG2/Dox cells[J].J Nat Prod,2008,71 : 1049-1059.
9Kokubo Y,Gemma A,Noro R,et al.Reduction of PTEN pro- tein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefetinib (Iressa)[J].Br J Cancer,2005,92 (9): 1711-1719.
5Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J].CA Cancer J Clin. 2013(63):11-30.
6Petrillo i, Borriello M, Fuoco G, et alNovel VEGF- independent Strategies Targeting Tumor Vasculature: Clinical Aspects[J].Current Pharmaceutical Design, 2012,18:2702-2712.
7Huang Z, Lin H, gang Y, Cao anti-angiogenic effect of Mar tract in vitro and in vivo[J] 917-922. Z, et sden al. Studies on the la Oncol tenacissima ex Lett,2013,5(3).
8Chatterjee S, Heukamp LC, Siobal M, et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers an- giogenesis in lung cancer[J].J Clin Invest,2013,123 (4):1732-1740.
9Yi ZF, Cho SG, Zhao H, et al.A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF induced human umbilical endothelial cellsEJ]. Int J Cancer,2009,124(4):843-852.
